| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2002;73:1558-1562
© 2002 The Society of Thoracic Surgeons
a Surgical Department of Respiratory Center, Mitsui Memorial Hospital, Tokyo, Japan
Accepted for publication December 21, 2001.
* Address reprint requests to Dr Kawano, Surgical Department of Respiratory Center, Mitsui Memorial Hospital, Kandaizumi-cho 1, Chiyoda-ku, Tokyo, Japan
e-mail: 2ryo{at}msc.biglobe.ne.jp
Background. To evaluate the frequency and clinicopathological characteristics of lymph node micrometastasis in left lung cancer patients diagnosed to be stage IA and IB based on routine histopathologic examinations, we examined the lymph nodes in patients who had undergone an extended mediastinal lymphadenectomy, using immunohistochemical methods.
Methods. Paraffin-embedded tissue sections from the lymph nodes in 49 patients with stage I left lung cancers were studied. We used AE1/AE3 as the anticytokeratin and Ber-EP4 as the antiepithelial cell antibodies when performing immunohistochemical staining.
Results. We identified micrometastasis of the lymph nodes in 13 (26.5%) of 49 patients with stage I left lung cancer. N0 disease was reclassified as N1 disease in 5 cases, N2 disease in 6 cases, and N3 disease in 2 cases. The location of the micrometastatic lymph nodes proved to be wide regions including the contralateral and highest mediastinal nodes, and 6 (46.2%) out of the 13 patients with micrometastasis were thus presumed not to be completely eliminated by a standard lymphadenectomy through an ipsilateral thoracotomy. The five year survival rate of patients with reclassified N1 to N3 disease was 74%, and the presence of micrometastasis was found to have no significant effect on the outcomes.
Conclusions. The micrometastatic involvement of the lymph nodes was both more frequent and extensive than expected even in stage I left lung cancer. These results suggest that an extended mediastinal lymphadenectomy may therefore be required for the locoregional control of stage I left lung cancer patients.
Related Article
Ann. Thorac. Surg. 2002 73: 1562.
This article has been cited by other articles:
|
|
 |
|
  Z. Mansour, E. A. Kochetkova, N. Santelmo, X. Ducrocq, E. Quoix, J.-M. Wihlm, and G. Massard Persistent n2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy. Ann. Thorac. Surg., July 1, 2008; 86(1): 228 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Schwartz and D. E. Henson Diagnostic Surgical Pathology in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 78S - 93S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sakao, H. Miyamoto, A. Yamazaki, T. Oh, R. Fukai, K. Shiomi, and Y. Saito Prognostic Significance of Metastasis to the Highest Mediastinal Lymph Node in Nonsmall Cell Lung Cancer Ann. Thorac. Surg., January 1, 2006; 81(1): 292 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Faries, R. J. Bleicher, X. Ye, R. Essner, and D. L. Morton Lymphatic Mapping and Sentinel Lymphadenectomy for Primary and Metastatic Pulmonary Malignant Neoplasms Arch Surg, August 1, 2004; 139(8): 870 - 877. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
